ESTRO 2024 - Abstract Book

S439

Clinical - Biomarkers

ESTRO 2024

Conclusion:

Serum IGF-1 level serve as a valube prognostic tool for the survival in HCC patients undergoing SBRT, even without disease progression. This insight may aid in tailoring less aggressive treatment strategies for those patients.

Keywords: HCC, SBRT, Biomarker

References:

1. RG de la, Garza RG de la, Morales-Garza LA, Martin-Estal I, Castilla-Cortazar I. Insulin-Like Growth Factor-1 Deficiency and Cirrhosis Establishment. J Clin Med Res [Internet]. 2017 Feb 20 ;9(4):233–47.

2. Cho EJ, Kim HC, Lee JH, Yoo JJ, Choi WM, Cho YY, Lee MJ, Cho Y, Lee DH, Lee Y Bin, et al. Serum insulin-like growth factor-1 predicts disease progression and survival in patients with hepatocellular carcinoma who undergo transarterial chemoembolization. PLoS One. 2014;9(3):1–7. 3. Kaseb AO, Guan Y, Yavuz BG, Abbas AR, Lu S, Hasanov E, Toh HC, Verret W, Wang Y. Serum IGF-1 Scores and Clinical Outcomes in the Phase III IMbrave150 Study of Atezolizumab Plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma. J Hepatocell Carcinoma [Internet]. 2022 Oct ;9:1065.

3125

Mini-Oral

Cold liver metastases according to a CD8 radiomic-score : a new target for SBRT with immunotherapy?

Roger Sun 1,2,3 , Markus Hecht 4 , Caroline Robert 5,6 , Emilie Routier 7,8 , Udo S Gaipl 9,10 , Benjamin Frey 9,10 , Rastilav Bahleda 11 , Charlotte Robert 1,2 , Piet Ost 12 , Eric Deutsch 1,2,3 1 Gustave Roussy, Radiotherapy, Villejuif, France. 2 Inserm, U1030, Villejuif, France. 3 Université Paris Saclay, Faculté de médecine, Kremlin Bicêtre, France. 4 Universitätsklinikum des Saarlandes, Klinik für Strahlentherapie und Radioonkologie, Saarland, Germany. 5 Gustave Roussy, Dermatology Unit, Department of Medicine, Villejuif, France. 6 Université Paris Saclay, Inserm U981, Villejuif, France. 7 Gusta, Dermatology Unit, Department of Medicine, Villejuif, France. 8 Université Paris Saclay, nserm U981, Villejuif, France. 9 Universitätsklinikum Erlangen, Department of Radiation Oncology, Erlangen, Germany. 10 Universitätsklinikum Erlangen, Translational Radiobiology, Erlangen, Germany. 11 Gustave Roussy, Drug Development Department, Villejuif, France. 12 Ghent University Hospital, Department for Radiation Oncology, Ghent, Belgium

Purpose/Objective:

Immunotherapy has revolutionized cancer treatment, but only a subset of patients (20-50%) benefit, underscoring the need for improved strategies and biomarkers to identify potential responders. Liver metastases significantly impact the survival of patients treated with immune checkpoint inhibitors (ICIs) (1,2). The liver's immunosuppressive environment may contribute to these negative effects on ICI efficacy (3), which focal radiotherapy may counteract by releasing tumor-associated antigens and enhancing lymphocyte trafficking (4). We have developed a radiomics signature of tumor CD8 T-Cells infiltration which has shown association with